Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Aerie Pharmaceuticals (NQ: AERI )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aerie Pharmaceuticals

< Previous 1 2 3 4 5 Next >
Why Zoom Video Is Trading Lower By 11%; Here Are 28 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 58.2% to $0.3070 in pre-market trading. Quotient recently reported a wider Q1 loss. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for a breakdown of the biggest pre-market stock movers for Tuesday and the news that has them moving. 
Via InvestorPlace
Palo Alto Networks, Aerie Pharmaceuticals And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Alcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma Portfolio
Via Benzinga
U.S. Stock Futures Edge Higher Following Monday's Sell-Off, Crude Oil Rises
Pre-open movers 
Via Benzinga
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday's Mid-Day Session
Gainers Assure Holdings Corp. (NASDAQ: IONM) shares jumped 88.8% to $3.9650 after jumping around 104% on Thursday. 
Via Benzinga
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease... 
Via Benzinga
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
HC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00. Shares of Aerie Pharmaceuticals are trading down... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the... 
Via Benzinga
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Earnings Preview For Aerie Pharmaceuticals
Aerie Pharmaceuticals (NASDAQ:AERI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Aerie... 
Via Benzinga
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Cannabis Movers & Shakers: SuperNet, MediPharm, Le-Vel, Jupiter Wellness, Leafly, Acreage
SuperNet Names John Pfisterer As CFO SuperNet, a payment network that enables credit card payments for cannabis merchants and consumers, has tapped John Pfisterer to oversee its financial department. 
Via Benzinga
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.